


What is claimed is:

1. A compound of Formula I:



or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:

n is 0, 1, 2, or 3;

R¹ is halo, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, C₁₋₆ alkoxy, cycloalkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, -C(O)R¹⁰, or -C(O)N(R¹¹)(R¹²), wherein each C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, C₁₋₆ alkoxy, cycloalkoxy, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R² is C₁₋₆ alkoxy, cycloalkyl, cycloalkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, or -N(R¹³)(R¹⁴), wherein each C₁₋₆ alkoxy, cycloalkyl, cycloalkoxy, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R³ is hydrogen or halo;

R⁴ is hydrogen, halo, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, heterocyclyl, heteroaryl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, -C(O)R¹⁰, or -C(O)N(R¹¹)(R¹²), wherein each C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, heterocyclyl, heteroaryl, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆ alkyl or cycloalkyl, or R⁵ and R⁶ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted;


R⁷ is halo or C₁₋₆ alkyl, wherein each C₁₋₆ alkyl is independently optionally substituted;

each R¹⁰ is independently C₁₋₆ alkyl or C₁₋₆ alkoxy, wherein each C₁₋₆ alkyl and C₁₋₆ alkoxy is independently optionally substituted;

each R¹¹ and R¹² are independently hydrogen, C₁₋₆ alkyl, cycloalkyl, or R¹¹ and R¹² together form an heterocyclyl group, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted; and

R¹³ and R¹⁴ are each independently hydrogen, C₁₋₆ alkyl, cycloalkyl, or R¹³ and R¹⁴ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted.

2. A compound of Formula IA:



or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:

n is 0, 1, 2, or 3;

R¹ is halo or optionally substituted C₁₋₆ alkyl;

R⁴ is hydrogen, halo, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, heterocyclyl, heteroaryl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, -C(O)R¹⁰, or -C(O)N(R¹¹)(R¹²), wherein each C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, heterocyclyl, heteroaryl, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆ alkyl or cycloalkyl, or R⁵ and R⁶ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted;


R⁷ is halo or C₁₋₆ alkyl, wherein each C₁₋₆ alkyl is independently optionally substituted;

each R¹⁰ is independently C₁₋₆ alkyl or C₁₋₆ alkoxy, wherein each C₁₋₆ alkyl and C₁₋₆ alkoxy is independently optionally substituted;

each R¹¹ and R¹² are independently hydrogen, C₁₋₆ alkyl, cycloalkyl, or R¹¹ and R¹² together form an heterocyclyl group, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted; and

R¹⁴ is C₁₋₆ alkyl or cycloalkyl, wherein each C₁₋₆ alkyl and cycloalkyl is independently optionally substituted.

3. The compound of claim 1 or 2, wherein R⁴ is other than optionally substituted cycloalkyl.
4. The compound of claim 3, wherein R⁴ is methyl.
5. The compound of any preceding claim, wherein n is 1.
6. The compound of any preceding claim, wherein R⁷ is optionally substituted C₁₋₆ alkyl.
7. The compound of any one of claims 1-5, wherein R⁷ is halo.
8. The compound of any one of claims 1-4, wherein n is 0.
9. The compound of any preceding claim, wherein R² is optionally substituted C₁₋₆ alkoxy, optionally substituted cycloalkyl, or -N(R¹³)(R¹⁴).
10. The compound of any preceding claim, wherein R² is -N(R¹³)(R¹⁴).
11. A compound of Formula IB:



or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:


R¹ is halo or optionally substituted C₁₋₆ alkyl;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆ alkyl or cycloalkyl, or R⁵ and R⁶ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted;

R¹⁴ is C₁₋₆ alkyl or cycloalkyl, wherein each C₁₋₆ alkyl and cycloalkyl is independently optionally substituted; and

R¹⁷ is hydrogen, halo or optionally substituted C₁₋₆ alkyl.

12. A compound of Formula IC:



or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:

R¹ is halo or optionally substituted C₁₋₆ alkyl;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆ alkyl or cycloalkyl, or R⁵ and R⁶ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted;

R¹⁴ is C₁₋₆ alkyl or cycloalkyl, wherein each C₁₋₆ alkyl and cycloalkyl is independently optionally substituted; and


R¹⁷ is hydrogen, halo or optionally substituted C₁₋₆ alkyl.

13. The compound of any preceding claim, wherein R¹ is halo, cyano, or C₁₋₆ alkyl optionally substituted with halo.


14. The compound of claim 13, wherein R¹ is halo.

15. The compound of claim 14, wherein R¹ is bromo.

16. The compound of claim 13, wherein R¹ is C₁₋₆ alkyl optionally substituted with one or more halo.
17. The compound of claim 16, wherein R¹ is C₁₋₆ haloalkyl.
18. The compound of claim 17, wherein R¹ is -CF₃.
19. The compound of any preceding claim, wherein R¹⁴ is optionally substituted C₁₋₆ alkyl.
20. The compound of any preceding claim, wherein R¹⁴ is methyl or ethyl.
21. The compound of any one of claims 1-18, wherein R¹⁴ is optionally substituted cycloalkyl.
22. The compound of claim 21, wherein R¹⁴ is cyclopropyl.
23. The compound of claim 21, wherein R¹⁴ is methylcyclopropyl.
24. The compound of claim 1, wherein n is 0; R¹ is halo, cyano, or C₁₋₆ alkyl optionally substituted with one or more halo; R² is -N(R¹³)(R¹⁴), where R¹³ is hydrogen and R¹⁴ is hydrogen, C₁₋₆ alkyl, or cycloalkyl; R³ is hydrogen or halo; R⁴ is methyl or cycloalkyl; and R⁵ and R⁶ are each independently hydrogen, C₁₋₆ alkyl or cycloalkyl.
25. A compound of Table 1 or Table 2, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof.
26. A pharmaceutical composition comprising a compound of any preceding claim, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
27. Use of a compound of any one of claims 1 to 25 for the manufacture of a medicament for treating a neurodegenerative disease, cancer, or an inflammatory disease.
28. Use of a compound of claim 27, wherein the cancer is kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, or multiple myeloma.
29. Use of a compound of claim 27, wherein the inflammatory disease is leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
30. Use of a compound of claim 27, wherein the inflammatory disease is Crohn's disease.
31. Use of a compound of claim 27, wherein the neurodegenerative disease is Parkinson's disease.
32. A method of preparing a compound of Formula I, or a salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof:



comprising coupling a compound of Formula I-1 with a compound of Formula I-2:



under conditions suitable to provide a compound of Formula I, wherein X is a leaving group, under conditions suitable to provide the compound of Formula I, or a salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:

n is 0, 1, 2, or 3;

R¹ is halo, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, C₁₋₆ alkoxy, cycloalkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, -C(O)R¹⁰, or -C(O)N(R¹¹)(R¹²), wherein each C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, C₁₋₆ alkoxy, cycloalkoxy, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R² is C₁₋₆ alkoxy, cycloalkyl, cycloalkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, or -N(R¹³)(R¹⁴), wherein each C₁₋₆ alkoxy, cycloalkyl, cycloalkoxy, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R³ is hydrogen or halo;

R⁴ is hydrogen, halo, cyano, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, heterocyclyl, heteroaryl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, -C(O)R¹⁰, or -C(O)N(R¹¹)(R¹²), wherein each C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, cycloalkyl, heterocyclyl, heteroaryl, C₁₋₆ alkylthio, and C₁₋₆ alkylsulfonyl is independently optionally substituted;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆ alkyl or cycloalkyl, or R⁵ and R⁶ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted;

R⁷ is halo or C₁₋₆ alkyl, wherein each C₁₋₆ alkyl is independently optionally substituted;

each R¹⁰ is independently C₁₋₆ alkyl or C₁₋₆ alkoxy, wherein each C₁₋₆ alkyl and C₁₋₆ alkoxy is independently optionally substituted;

each R¹¹ and R¹² are independently hydrogen, C₁₋₆ alkyl, cycloalkyl, or R¹¹ and R¹² together form an heterocyclyl group, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted; and

R¹³ and R¹⁴ are each independently hydrogen, C₁₋₆ alkyl, cycloalkyl, or R¹³ and R¹⁴ together form a heterocyclyl, wherein each C₁₋₆ alkyl, cycloalkyl, and heterocyclyl is independently optionally substituted.

33. The method of claim 32, wherein X is halo.